Valeant Plans $1.45B Stock Offering To Fund Salix Buy
Canadian drug giant Valeant Pharmaceuticals Inc. priced a $1.45 billion stock offering at $199 per share Tuesday to help fund its blockbuster $15.8 billion purchase for gastrointestinal treatments maker Salix Pharmaceuticals...To view the full article, register now.
Already a subscriber? Click here to view full article